查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1380016

肺氣腫治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療、按配銷通路、按最終用戶按地區和競爭細分

Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment, By Distribution Channel, By End-User By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球肺氣腫治療市場價值為 42.1 億美元，預計在預測期內將強勁成長，到 2028 年CAGR為5.68%。全球肺氣腫治療市場是醫療保健行業中一個充滿活力且快速發展的領域，主要是肺氣腫是一種慢性阻塞性肺病（COPD），其發生率不斷上升。肺氣腫的特徵是肺組織遭到破壞，導致呼吸急促和肺功能下降。這種令人衰弱的狀況通常是由長期接觸菸草煙霧、環境污染物和其他危險因子引起的。因此，對有效肺氣腫治療的需求不斷增加，推動了該市場的成長。

全球肺氣腫治療市場成長的關鍵驅動力之一是旨在尋找創新療法和介入措施的持續研究和開發工作。肺氣腫的傳統治療方法主要包括藥物、氧氣治療和肺康復。然而，近年來醫療技術的進步導致支氣管鏡肺減容術（BLVR）和肺移植等微創手術的出現，為嚴重肺氣腫患者帶來了新的希望。

此外，市場上正在見證大量新型醫藥產品和療法的湧入，包括支氣管擴張劑、抗發炎藥物和針對肺氣腫進展特定途徑的生物製劑。這些創新療法旨在改善患者的生活品質並減緩疾病的進展。然而，治療成本高、某些地區獲得先進療法的機會有限以及需要進行嚴格的臨床試驗以確定新療法的有效性和安全性等挑戰仍然是市場擴張的障礙。

市場概況
預測期 2024-2028
2022 年市場規模 42.1億美元
2028 年市場規模 58.2億美元
2023-2028 年CAGR 5.68%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

主要市場促進因素

醫療科技的進步

醫療技術的進步在推動全球肺氣腫治療市場方面發揮關鍵作用。肺氣腫是一種使人衰弱的慢性阻塞性肺病（COPD），歷來為治療帶來了重大挑戰。然而，醫療技術的最新突破正在徹底改變肺氣腫治療的面貌。

肺氣腫盛行率上升

肺氣腫盛行率的上升是全球肺氣腫治療市場成長的重要動力。肺氣腫是一種慢性阻塞性肺病（COPD），其特徵是肺組織進行性破壞，導致嚴重的呼吸困難和肺功能下降。肺氣腫的主要危險因子包括長期暴露於菸草煙霧、環境污染物和職業危害，所有這些在現代社會中都變得越來越普遍。

隨著全球人口老化和這些危險因子的持續存在，肺氣腫的盛行率持續攀升。世界衛生組織 (WHO) 估計，包括肺氣腫在內的慢性阻塞性肺病 (COPD) 已成為全球第三大死因，而這一負擔預計在未來幾年將進一步增加。在許多已開發國家，人口老化導致肺氣腫盛行率較高，因為這種疾病在老年人中更為常見。

此外，肺氣腫與心臟病和糖尿病等其他健康狀況之間的關聯強調了解決這種疾病的緊迫性。它給醫療保健系統帶來了沉重的負擔，導致住院和醫療費用增加。因此，醫療保健提供者和政策制定者都認知到早期診斷和有效治療的重要性，以減輕肺氣腫對個人和醫療資源的影響。

人們對肺氣腫和慢性阻塞性肺病的認知不斷提高也促進了市場的成長。公共衛生計劃、教育活動和倡導團體有助於提高人們對吸菸、環境污染相關風險以及早期發現和管理呼吸道疾病重要性的認知。這種意識的提高鼓勵人們在疾病的早期階段就醫，以便及時介入和治療。

提高認知和教育

提高意識和教育在推動全球肺氣腫治療市場方面發揮關鍵作用。肺氣腫是慢性阻塞性肺病 (COPD) 的一種嚴重形式，長期以來一直未被充分診斷​​和治療。然而，教育和宣傳活動的共同努力正在改變這種說法。

公共衛生計劃和倡導團體一直在積極提高人們對肺氣腫和慢性阻塞性肺病相關風險的認知。這些努力的重點是吸煙的危害、環境污染以及早期發現和治療的重要性。因此，越來越多的人了解肺氣腫的危險因子和症狀，從而實現早期診斷和介入。

意識的提高導致患者行為發生重大轉變。現在，當人們出現呼吸短暫和慢性咳嗽等症狀時，他們更有可能尋求醫療協助，這些症狀通常是肺氣腫的早期徵兆。這種積極主動的方法可以及時診斷並啟動適當的治療，最終改善患者的治療結果。

此外，醫療保健提供者擴大了解肺氣腫治療方案的最新進展。他們更有能力識別疾病並推薦適當的治療方法。這不僅使患者受益，而且還支持肺氣腫治療市場的成長，因為醫療保健專業人員積極致力於為患者提供創新治療。

由於意識的提高，研究經費也有所增加。隨著對該疾病的影響和對有效治療的迫切需求有了更深入的了解，公共和私營部門都在投資研究和開發工作。這導致了新的創新療法的開發，進一步擴大了肺氣腫患者可用的治療選擇。

主要市場挑戰

治療費用高

高治療成本是阻礙全球肺氣腫治療市場發展的重大障礙。肺氣腫是一種使人衰弱的慢性阻塞性肺病 (COPD)，影響著全世界數百萬人，治療這種疾病可能會對患者和醫療保健系統造成經濟負擔。

創新型肺氣腫治療方法的發展，例如支氣管鏡肺減容術（BLVR）和標靶生物製劑，透過提供潛在的更有效和侵入性更小的選擇，為患者帶來了新的希望。然而，這些尖端治療方法通常價格昂貴。

對許多肺氣腫患者來說，高昂的治療費用構成了巨大的經濟障礙。應對這些療法的經濟負擔可能是巨大的，特別是對於那些沒有全面健康保險的人來說。高免賠額、共付額和自付費用可能會對患者的財務造成壓力，並限制他們獲得基本治療的機會。

此外，肺氣腫是一種慢性疾病，通常需要持續護理，包括藥物治療、定期檢查和肺部康復。這些長期費用進一步加劇了患者面臨的財務挑戰，可能迫使他們在醫療保健和其他基本需求之間做出艱難的選擇。

高額治療費用的負擔也延伸到醫療保健系統和政府。隨著肺氣腫盛行率持續上升，醫療預算的壓力變得更加明顯。提供先進治療和療法的成本可能會導致分配挑戰，從而從其他關鍵醫療保健需求中轉移資源。

長期疾病管理

長期疾病管理對全球肺氣腫治療市場的發展構成了重大障礙。肺氣腫是慢性阻塞性肺病 (COPD) 的一種形式，是一種進行性肺部疾病，需要持續護理和管理。儘管已經出現了創新的治療和干涉措施，但長期有效管理肺氣腫給患者和醫療保健系統帶來了一些挑戰。

肺氣腫患者通常需要持續接受藥物、治療和醫療監督，以維持他們的生活品質。這給醫療保健系統帶來了巨大的經濟負擔，因為提供長期照護和藥物的成本可能很高。對於患者來說，確保持續獲得​​治療可能具有挑戰性，特別是對於那些經濟資源有限或醫療保險覆蓋範圍不足的患者。

生活方式的改變是肺氣腫治療的一個重要方面，包括戒菸、定期運動和飲食改變。鼓勵患者長期採用並維持這些改變可能是一項艱鉅的挑戰。患者可能會缺乏動力，自我管理的負擔可能導致不遵守建議的生活方式調整。

此外，肺氣腫是一種動態疾病，這意味著隨著病情的進展，治療計劃和療法可能需要調整。這需要醫療保健提供者進行密切和持續的監測。然而，定期獲得醫療保健並遵守治療計劃對於患者來說可能具有挑戰性，特別是那些居住在偏遠地區或行動不便的患者。

主要市場趨勢

採用微創手術

微創手術的採用在推動全球肺氣腫治療市場方面發揮關鍵作用。肺氣腫是一種以肺組織破壞為特徵的進行性肺部疾病，傳統上與侵入性手術治療或長期藥物治療有關。然而，醫療技術的最新進步導致了微創手術的發展和廣泛採用，為肺氣腫的治療方式帶來了典範轉移。

微創手術發展的最重要貢獻者之一是支氣管鏡肺減容術 (BLVR) 技術的出現。 BLVR 涉及將小型裝置或材料插入氣道，以阻止或減少流向受損肺部區域的氣流。該手術旨在改善肺功能並減輕症狀，而無需進行開放性手術。與傳統手術方法相比，患者可以受益於更短的住院時間、更快的康復時間以及更低的併發症風險。

微創手術的吸引力不僅在於其有效性。這取決於他們以患者為中心的方法。患者更傾向於選擇侵入性較小的治療，這些治療可以提供更快的恢復時間和更低的併發症風險。因此，醫療保健提供者擴大推薦並實施 BLVR 和其他微創手術，以滿足患者的偏好和期望。

此外，微創手術的採用符合醫療保健領域基於價值的護理和成本效益的更廣泛趨勢。由於住院時間縮短和術後護理減少，這些手術通常會降低醫療成本，使患者和醫療保健系統受益。

肺氣腫治療中生物製劑的興起

肺氣腫治療中生物製劑的興起顯著推動了全球肺氣腫治療市場。肺氣腫是慢性阻塞性肺病 (COPD) 的一種使人衰弱的疾病，歷來採用支氣管擴張劑、皮質類固醇和氧氣治療進行治療。然而，醫學科學的最新進展導致了生物製劑的開發和增加使用，代表了管理這種具有挑戰性的呼吸系統疾病的方法的範式轉移。

生物製劑是源自活生物體的治療劑，例如單株抗體或蛋白質，旨在針對參與肺氣腫進展的特定分子途徑。與緩解症狀的傳統療法不同，生物製劑提供了一種有針對性的方法，旨在減緩潛在的疾病進程。這種創新方法引起了醫學界和患者的極大關注和熱情。

生物製劑的主要優點之一是它們有可能改善肺氣腫患者的肺功能和整體生活品質。透過專門針對導致肺氣腫中組織破壞和發炎的分子機制，這些治療不僅有可能減輕症狀，而且有可能改變病程。這代表了對主要關注症狀管理的傳統方法的根本轉變。

此外，生物製劑往往具有良好的安全性，可降低通常與長期使用皮質類固醇或其他藥物相關的全身性副作用的風險。這使得生物學對於患者和醫療保健提供者來說成為有吸引力的選擇，特別是對於那些可能擔心傳統治療的潛在風險和副作用的人來說。

細分市場洞察

治療見解

基於此治療，戒菸將成為2022年全球肺氣腫治療市場的主導部分。戒菸被認為是肺氣腫最有效、最首要的預防措施。由於肺氣腫的主要原因是長期接觸菸草煙霧，因此戒菸對於防止疾病進一步發展或進展至關重要。這導致人們非常重視戒菸計畫和介入措施。

與基因治療、手術或肺移植等其他肺氣腫治療方法相比，戒菸相對具有成本效益。這種負擔能力使其成為醫療保健系統和個人的實用選擇，特別是在考慮與治療肺氣腫相關的長期成本時。

配銷通路洞察

根據配銷通路，零售藥房細分市場將成為 2022 年全球肺氣腫治療市場的主導者。無論是在城市還是農村地區，絕大多數人都可以輕鬆進入零售藥房。患有肺氣腫和其他呼吸系統疾病的患者通常需要定期接受藥物和治療。零售藥局為患者提供了取得處方和醫療用品的便利選擇，提高了治療順從性。

零售藥房連鎖店擁有廣泛的銷售網路，使患者可以輕鬆找到附近的藥房。這種廣泛的覆蓋範圍確保了城市和農村地區不同地理位置的患者可以隨時獲得肺氣腫藥物和治療用品。

區域洞察

2022年，北美成為全球肺氣腫治療市場的主導者，佔據最大的市場佔有率。北美，尤其是美國，肺氣腫和其他慢性阻塞性肺病（COPD）的盛行率很高。這種高疾病負擔導致對肺氣腫治療方案的巨大需求，推動了市場的成長。北美擁有先進的醫療保健基礎設施，包括設備齊全的醫院、專科診所和醫療保健提供者網路。該基礎設施透過最新的醫療技術和療法來支持肺氣腫的診斷、治療和管理。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：全球肺氣腫治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療方法（戒菸、支氣管擴張劑、類固醇、白三烯調節劑、補充氧氣、抗生素、基因治療、手術移植、其他治療）
    • 按配銷通路（醫院藥房、零售藥房、其他分銷管道）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 按治療
    • 按配銷通路
    • 按最終用戶
    • 按地區

第 5 章：亞太地區肺氣腫治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國肺氣腫治療
    • 印度肺氣腫治療
    • 澳洲肺氣腫治療
    • 日本肺氣腫治療
    • 韓國肺氣腫治療

第 6 章：歐洲肺氣腫治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美肺氣腫治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲肺氣腫治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲肺氣腫治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療
    • 按配銷通路
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非肺氣腫治療
    • 沙烏地阿拉伯肺氣腫治療
    • 阿拉伯聯合大公國肺氣腫治療
    • 埃及肺氣腫治療

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球肺氣腫治療市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Icure 製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Current Capacity Analysis
    • Financials (In case of listed)
    • Recent Developments
    • SWOT Analysis
  • 阿斯特捷利康公司
  • 梯瓦製藥工業股份有限公司
  • 諾華公司
  • 葛蘭素史克公司
  • 希克瑪製藥公司
  • 勃林格殷格翰國際股份有限公司
  • 邁蘭公司
  • 輝瑞公司
  • 獵戶座公司

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 17479

Global Emphysema Treatment Market has valued at USD 4.21 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.68% through 2028. The Global Emphysema Treatment Market is a dynamic and rapidly evolving sector within the healthcare industry, primarily driven by the increasing prevalence of emphysema, a chronic obstructive pulmonary disease (COPD). Emphysema is characterized by the destruction of lung tissue, leading to shortness of breath and reduced lung function. This debilitating condition is often caused by long-term exposure to tobacco smoke, environmental pollutants, and other risk factors. As a result, the demand for effective emphysema treatments has been on the rise, fueling the growth of this market.

One of the key drivers behind the growth of the Global Emphysema Treatment Market is the continuous research and development efforts aimed at finding innovative therapies and interventions. Traditional treatments for emphysema primarily include medications, oxygen therapy, and pulmonary rehabilitation. However, recent advancements in medical technology have led to the emergence of minimally invasive procedures like bronchoscopic lung volume reduction (BLVR) and lung transplantation, offering new hope to patients with severe emphysema.

Furthermore, the market is witnessing an influx of novel pharmaceutical products and therapies, including bronchodilators, anti-inflammatory drugs, and biologics that target specific pathways involved in emphysema progression. These innovative treatments aim to improve patients' quality of life and slow down the disease's progression. However, challenges such as high treatment costs, limited access to advanced therapies in certain regions, and the need for rigorous clinical trials to establish the efficacy and safety of new treatments remain hurdles in the market's expansion.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.21 Billion
Market Size 2028USD 5.82 Billion
CAGR 2023-20285.68%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers

Advancements in Medical Technology

Advancements in medical technology are playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), has historically posed significant challenges in treatment. However, recent breakthroughs in medical technology are revolutionizing the landscape of emphysema management.

Minimally invasive procedures like bronchoscopic lung volume reduction (BLVR) have emerged as a game-changer in emphysema treatment. BLVR involves the insertion of small devices or materials into the airways to block off or reduce airflow to damaged areas of the lungs. This procedure helps improve lung function and alleviate symptoms, offering a lifeline to patients with severe emphysema who were previously deemed untreatable. BLVR not only reduces the burden of invasive surgery but also enhances patient outcomes and quality of life.

Biologics and targeted therapies represent another breakthrough in emphysema treatment. These pharmaceutical innovations are designed to specifically target the underlying molecular pathways responsible for emphysema progression. By intervening at the molecular level, biologics can slow down the disease's advancement and improve patients' respiratory function. This approach is not only more effective but also less invasive compared to traditional treatment options like long-term corticosteroids or bronchodilators.

Furthermore, technological advancements have led to improved diagnostic tools and monitoring devices. High-resolution computed tomography (HRCT) scans, for instance, provide more accurate and detailed images of lung damage caused by emphysema. These diagnostic improvements enable healthcare professionals to assess the severity of the disease and tailor treatment plans more precisely.

Rising Prevalence of Emphysema

The rising prevalence of emphysema is a significant driving force behind the growth of the Global Emphysema Treatment Market. Emphysema, a chronic obstructive pulmonary disease (COPD), is characterized by the progressive destruction of lung tissue, leading to severe respiratory difficulties and reduced lung function. The primary risk factors for emphysema include long-term exposure to tobacco smoke, environmental pollutants, and occupational hazards, all of which have become increasingly prevalent in modern society.

As the global population ages and these risk factors persist, the prevalence of emphysema continues to climb. The World Health Organization (WHO) estimates that COPD, including emphysema, is already the third leading cause of death worldwide, and this burden is expected to increase further in the coming years. In many developed countries, an aging population contributes to a higher prevalence of emphysema, as the disease is more common among older individuals.

Furthermore, the link between emphysema and other health conditions, such as heart disease and diabetes, underscores the urgency of addressing this disease. It places a substantial burden on healthcare systems, with increased hospitalizations and healthcare costs. As a result, both healthcare providers and policymakers are recognizing the importance of early diagnosis and effective treatment to mitigate the impact of emphysema on individuals and healthcare resources.

The rising awareness of emphysema and COPD in general is also contributing to the market's growth. Public health initiatives, educational campaigns, and advocacy groups have been instrumental in increasing awareness about the risks associated with smoking, environmental pollution, and the importance of early detection and management of respiratory diseases. This heightened awareness encourages individuals to seek medical attention at an earlier stage of the disease, enabling timely intervention and treatment.

Increasing Awareness and Education

Increasing awareness and education are playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a severe form of chronic obstructive pulmonary disease (COPD), has long been underdiagnosed and undertreated. However, concerted efforts in education and awareness campaigns are changing this narrative.

Public health initiatives and advocacy groups have been actively raising awareness about the risks associated with emphysema and COPD. These efforts have focused on the dangers of smoking, environmental pollution, and the importance of early detection and treatment. As a result, more individuals are becoming informed about the risk factors and symptoms of emphysema, leading to early diagnosis and intervention.

Increased awareness has led to a significant shift in patient behavior. Individuals are now more likely to seek medical attention when they experience symptoms like shortness of breath and chronic cough, which are often early indicators of emphysema. This proactive approach allows for timely diagnosis and the initiation of appropriate treatments, ultimately improving patient outcomes.

Moreover, healthcare providers are increasingly educated about the latest advancements in emphysema treatment options. They are better equipped to recognize the disease and recommend appropriate therapies. This not only benefits patients but also supports the growth of the emphysema treatment market as healthcare professionals actively engage in providing innovative treatments to their patients.

Research funding has also seen an uptick due to increased awareness. With a greater understanding of the disease's impact and the urgent need for effective treatments, both public and private sectors are investing in research and development efforts. This has led to the development of new and innovative therapies, further expanding the treatment options available to individuals with emphysema.

Key Market Challenges

High Treatment Costs

High treatment costs are a significant barrier hindering the advancement of the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), affects millions of individuals worldwide, and managing this condition can be financially burdensome for both patients and healthcare systems.

The development of innovative emphysema treatments, such as bronchoscopic lung volume reduction (BLVR) procedures and targeted biologics, has offered new hope to patients by providing potentially more effective and less invasive options. However, these cutting-edge treatments often come with a hefty price tag.

For many emphysema patients, the high cost of treatment represents a substantial financial barrier. Coping with the financial burden of these therapies can be overwhelming, particularly for those without comprehensive health insurance coverage. High deductibles, copayments, and out-of-pocket expenses can strain patients' finances and limit their access to essential treatments.

Additionally, emphysema is a chronic condition that often requires ongoing care, including medications, regular check-ups, and pulmonary rehabilitation. These long-term expenses further compound the financial challenges faced by patients, potentially forcing them to make difficult choices between healthcare and other essential needs.

The burden of high treatment costs also extends to healthcare systems and governments. As the prevalence of emphysema continues to rise, the strain on healthcare budgets becomes more pronounced. The cost of providing advanced treatments and therapies can lead to allocation challenges, diverting resources from other critical healthcare needs.

Long-Term Disease Management

Long-term disease management poses a significant hindrance to the advancement of the Global Emphysema Treatment Market. Emphysema, a form of chronic obstructive pulmonary disease (COPD), is a progressive lung condition that requires ongoing care and management. While innovative treatments and interventions have emerged, effectively managing emphysema over the long term presents several challenges for both patients and healthcare systems.

Emphysema patients often require continuous access to medications, therapies, and medical supervision to maintain their quality of life. This entails a substantial financial burden on healthcare systems, as the cost of providing long-term care and medication can be significant. For patients, ensuring consistent access to treatment can be challenging, especially for those with limited financial resources or inadequate health insurance coverage.

Lifestyle modifications are a crucial aspect of emphysema management, including smoking cessation, regular exercise, and dietary changes. Encouraging patients to adopt and maintain these changes over the long term can be a formidable challenge. Patients may struggle with motivation, and the burden of self-management can lead to non-compliance with recommended lifestyle adjustments.

Furthermore, emphysema is a dynamic disease, meaning that as it progresses, treatment plans and therapies may need adjustments. This necessitates close and ongoing monitoring by healthcare providers. However, accessing healthcare regularly and adhering to treatment plans can be challenging for patients, particularly those who live in remote areas or have limited mobility.

Key Market Trends

Adoption of Minimally Invasive Procedures

The adoption of minimally invasive procedures is playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a progressive lung condition characterized by the destruction of lung tissue, has traditionally been associated with invasive surgical treatments or long-term medication. However, recent advancements in medical technology have led to the development and widespread adoption of minimally invasive procedures, offering a paradigm shift in the way emphysema is treated.

One of the most significant contributors to the growth of minimally invasive procedures is the emergence of bronchoscopic lung volume reduction (BLVR) techniques. BLVR involves the insertion of small devices or materials into the airways to block or reduce airflow to damaged lung areas. This procedure aims to improve lung function and alleviate symptoms without the need for open surgery. Patients benefit from shorter hospital stays, faster recovery times, and reduced risk of complications compared to traditional surgical approaches.

The appeal of minimally invasive procedures goes beyond their effectiveness; it lies in their patient-centric approach. Patients are more inclined to opt for less invasive treatments that offer quicker recovery times and a lower risk of complications. As a result, healthcare providers increasingly recommend and perform BLVR and other minimally invasive procedures, meeting the preferences and expectations of patients.

Moreover, the adoption of minimally invasive procedures aligns with the broader trend in healthcare toward value-based care and cost-effectiveness. These procedures typically lead to reduced healthcare costs due to shorter hospital stays and less post-operative care, benefiting both patients and healthcare systems.

Rise of Biologics in Emphysema Treatment

The rise of biologics in emphysema treatment is significantly boosting the Global Emphysema Treatment Market. Emphysema, a debilitating form of chronic obstructive pulmonary disease (COPD), has historically been treated with bronchodilators, corticosteroids, and oxygen therapy. However, recent advancements in medical science have led to the development and increasing use of biologics, representing a paradigm shift in the approach to managing this challenging respiratory condition.

Biologics are therapeutic agents derived from living organisms, such as monoclonal antibodies or proteins, designed to target specific molecular pathways involved in emphysema progression. Unlike traditional treatments that provide symptomatic relief, biologics offer a targeted approach, aiming to slow down the underlying disease process. This innovative approach has garnered significant attention and enthusiasm within the medical community and among patients.

One of the key advantages of biologics is their potential to improve lung function and overall quality of life for emphysema patients. By specifically targeting the molecular mechanisms responsible for the tissue destruction and inflammation seen in emphysema, these treatments have the potential to not only alleviate symptoms but also modify the course of the disease. This represents a fundamental shift from the traditional approach, which primarily focused on symptom management.

Additionally, biologics tend to have a favorable safety profile, reducing the risk of systemic side effects often associated with long-term use of corticosteroids or other medications. This makes biology an attractive option for patients and healthcare providers alike, especially for those who may have concerns about the potential risks and side effects of traditional treatments.

Segmental Insights

Treatment Insights

Based on the Treatment, Smoking Cessation emerged as the dominant segment in the global market for Global Emphysema Treatment Market in 2022. Smoking cessation is considered the most effective and primary preventive measure for emphysema. Since the leading cause of emphysema is long-term exposure to tobacco smoke, stopping smoking is crucial in preventing the disease from developing or progressing further. This has led to a significant emphasis on smoking cessation programs and interventions.

Smoking cessation is relatively cost-effective when compared to other emphysema treatments like gene therapy, surgery, or lung transplantation. This affordability makes it a practical choice for healthcare systems and individuals, especially when considering the long-term costs associated with managing emphysema.

Distribution Channel Insights

Based on the Distribution Channel, the Retail pharmacy segment emerged as the dominant player in the global market for Global Emphysema Treatment Market in 2022. Retail pharmacies are easily accessible to a vast majority of the population, whether in urban or rural areas. Patients with emphysema and other respiratory conditions often require regular access to medications and therapies. Retail pharmacies provide a convenient option for patients to obtain their prescriptions and medical supplies, promoting treatment adherence.

Retail pharmacy chains have a broad network of outlets, making it easy for patients to find a nearby pharmacy. This wide coverage ensures that emphysema medications and treatment supplies are readily available to patients across various geographical locations, both in cities and rural areas.

Regional Insights

North America emerged as the dominant player in the global Emphysema Treatment Market in 2022, holding the largest market share. North America, particularly the United States, has a significant prevalence of emphysema and other chronic obstructive pulmonary diseases (COPD). This high disease burden contributes to a substantial demand for emphysema treatment options, driving the market's growth. North America boasts advanced healthcare infrastructure, including well-equipped hospitals, specialized clinics, and a network of healthcare providers. This infrastructure supports the diagnosis, treatment, and management of emphysema with the latest medical technologies and therapies.

Key Market Players

  • Icure Pharmaceuticals Inc.
  • AstraZeneca Plc.
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Hikma Pharmaceuticals Plc
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Pfizer Inc.
  • Orion Corporation

Report Scope:

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Emphysema Treatment Market, By Treatment:

  • Smoking Cessation
  • Bronchodilators
  • Steroids
  • Leukotriene Modifiers
  • Supplemental Oxygen
  • Antibiotics
  • Gene Therapy
  • Surgery Transplant
  • Other Treatments

Global Emphysema Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

Global Emphysema Treatment Market, By End User:

  • Hospitals &Clinics
  • Ambulatory Surgical Centers
  • Other

Global Emphysema Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market.

Available Customizations:

  • Global Emphysema Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Emphysema Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments)
    • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
    • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Treatment
    • 4.3.2. By Distribution Channel
    • 4.3.3. By End-User
    • 4.3.4. By Region

5. Asia Pacific Emphysema Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment
    • 5.2.2. By Distribution Channel
    • 5.2.3. By End-User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Emphysema Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment
        • 5.3.1.2.2. By Distribution Channel
        • 5.3.1.2.3. By End-User
    • 5.3.2. India Emphysema Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment
        • 5.3.2.2.2. By Distribution Channel
        • 5.3.2.2.3. By End-User
    • 5.3.3. Australia Emphysema Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment
        • 5.3.3.2.2. By Distribution Channel
        • 5.3.3.2.3. By End-User
    • 5.3.4. Japan Emphysema Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment
        • 5.3.4.2.2. By Distribution Channel
        • 5.3.4.2.3. By End-User
    • 5.3.5. South Korea Emphysema Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment
        • 5.3.5.2.2. By Distribution Channel
        • 5.3.5.2.3. By End-User

6. Europe Emphysema Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Emphysema Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.3. By End-User
    • 6.3.2. Germany Emphysema Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Distribution Channel
        • 6.3.2.2.3. By End-User
    • 6.3.3. Spain Emphysema Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Distribution Channel
        • 6.3.3.2.3. By End-User
    • 6.3.4. Italy Emphysema Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment
        • 6.3.4.2.2. By Distribution Channel
        • 6.3.4.2.3. By End-User
    • 6.3.5. United Kingdom Emphysema Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment
        • 6.3.5.2.2. By Distribution Channel
        • 6.3.5.2.3. By End-User

7. North America Emphysema Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Distribution Channel
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Emphysema Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Distribution Channel
        • 7.3.1.2.3. By End-User
    • 7.3.2. Mexico Emphysema Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Distribution Channel
        • 7.3.2.2.3. By End-User
    • 7.3.3. Canada Emphysema Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Distribution Channel
        • 7.3.3.2.3. By End-User

8. South America Emphysema Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Emphysema Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Distribution Channel
        • 8.3.1.2.3. By End-User
    • 8.3.2. Argentina Emphysema Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Distribution Channel
        • 8.3.2.2.3. By End-User
    • 8.3.3. Colombia Emphysema Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Distribution Channel
        • 8.3.3.2.3. By End-User

9. Middle East and Africa Emphysema Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Distribution Channel
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Emphysema Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Distribution Channel
        • 9.3.1.2.3. By End-User
    • 9.3.2. Saudi Arabia Emphysema Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Distribution Channel
        • 9.3.2.2.3. By End-User
    • 9.3.3. UAE Emphysema Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Distribution Channel
        • 9.3.3.2.3. By End-User
    • 9.3.4. Egypt Emphysema Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Treatment
        • 9.3.4.2.2. By Distribution Channel
        • 9.3.4.2.3. By End-User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Emphysema Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Icure Pharmaceuticals Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. AstraZeneca Plc.
  • 14.3. Teva Pharmaceuticals Industries Ltd.
  • 14.4. Novartis AG
  • 14.5. GlaxoSmithKline Plc.
  • 14.6. Hikma Pharmaceuticals Plc
  • 14.7. Boehringer Ingelheim International GmbH
  • 14.8. Mylan N.V.
  • 14.9. Pfizer Inc.
  • 14.10. Orion Corporation

15. Strategic Recommendations

16. About Us & Disclaimer